ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody

... LEUVEN Belgium LUND Sweden and BASEL Switzerland June 18/PRN...Under the terms of the agreement effective from June 17 2008 (or if a...ThromboGenics and BioInvent are responsible for any remaining costsas...

LEUVEN, Belgium, LUND, Sweden and BASEL, Switzerland, June 18
/PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and
BioInvent International AB (Nordic Exchange: BINV) announce that they have
entered into a license agreement with Roche (SWX: ROG) for their jointly
developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody
which blocks Placental Growth Factor (PIGF), one of the growth factors
responsible for the development of new blood vessels.

Under the terms of the agreement effective from June 17, 2008 (or if a
U.S. anti-trust clearance is required, from the date of receipt of such
clearance), Roche will pay ThromboGenics and BioInvent an upfront payment
of EUR50 million. In addition, ThromboGenics and BioInvent could
potentially receive up to EUR450 million over the term of the collaboration
based on the successful completion of a series of development and
commercial milestones for multiple indications, as well as double digit
royalties on potential product sales, including any backup antibodies based
on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive
60% and BioInvent 40% of the revenue from the deal. Roche will have a
worldwide, exclusive license to develop and commercialize TB-403.
ThromboGenics and BioInvent will retain co-promotion rights for the product
in the Benelux, Baltic and Nordic regions.

ThromboGenics and BioInvent are responsible for any remaining costs
associated with the recently completed Phase Ia trial in healthy
volunteers. Roche will assume responsibility for all future development
costs for this novel therapy, including the costs of the pending Phase Ib
trial in patients to be run by ThromboGenics and BioInvent. ThromboGenics
and BioInvent in conjunction with Roche will form a Joint Steering
Committee to oversee research and development activities. In addition,
Roche will also provide funding to ThromboGenics and BioInvent for research
on non-cancer indications and supply of clinical material until transfer of
manufacturing.

TB-403 (Anti-PIGF) has completed an initial Phase I clinical trial and
recently received approval to enter a Phase Ib dose escalation trial. This
Phase Ib trial will be conducted in patients with advanced cancer and is
due to commence shortly in Denmark.

TB-403 has the potential to be a major advance in the treatment of
cancer. It is a humanized monoclonal antibody that blocks the formation of
the new blood vessels that are needed by solid tumours to support their
growth. TB-403 has the potential to minimize both the growth and spread of
cancer cells.

Professor Désiré Collen, CEO and Chairman of ThromboGenics, said:
"TB-403 has generated a great deal of interest from the pharmaceutical
community. Therefore, we are delighted that we have signed this major
licensing agreement with Roche, given their expertise and success in
bringing novel anti-cancer agents to the market. This deal represents a
significant milestone in ThromboGenics' development as a company. It also
reflects TB-403's potential as a promising treatment for cancer, and is a
testament to the hard work and high quality science on which ThromboGenics'
business is based. The funding from this deal also gives us the financial
resources to continue to build our strong pipeline. We look forward to
working with Roche, and to the successful development of this unique
anti-cancer agent."

Svein Mathisen, CEO of BioInvent, commented on the deal: "We believe
that TB-403 has great potential for the treatment of cancer, with its
unique mode of action targeting PlGF, and are delighted that Roche has
recognised this potential. This agreement demonstrates our ability to
identify innovative projects and to realize the clinical potential of a
therapeutic antibody. We look forward to seeing the product progress
further through clinical development and towards market."

Dan Zabrowski, Global Head of Pharma Partnering, Roche added; "We are
very pleased to enter this partnership with ThromboGenics and BioInvent.
This novel antibody, TB-403 has the potential to play a major role in the
treatment of cancer and we are committed to driving ahead with its
development. In addition, we look forward to developing a strong working
relationship with ThromboGenics and BioInvent."

Notes to Editors:

About TB-403

TB-403 was in-licensed by ThromboGenics from the Flanders Institute for
Biotechnology (VIB) at the University of Leuven, Belgium, where the
therapeutic potential of anti-PlGF agents to treat cancer was first
developed in the laboratory of Prof. Peter Carmeliet.

Angiogenesis inhibitors such as TB-403 are therapeutic agents that work
by blocking the development of new blood vessels, thereby depriving growing
cancer tumour cells of oxygen and nutrients. This approach in turn is
thought to stop the tumour from growing and spreading to other parts of the
body. PlGF is a homologue of VEGF and current preclinical evidence suggests
that it may not affect normal, physiological angiogenesis and is
predominantly involved in angiogenesis of malignant tissue.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and
development of biopharmaceuticals for the treatment of a range of vascular
diseases. The Company has several programs in Phase II clinical development
including microplasmin, which is being evaluated as a treatment for
vitreoretinal disorders and as a thrombolytic agent for vascular occlusive
diseases, including acute stroke. ThromboGenics is also developing novel
antibody therapeutics in collaboration with BioInvent International; these
include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical
development in 2008, and TB-403 (Anti-PlGF). ThromboGenics and BioInvent
have recently signed a license agreement with Roche for TB-403 worth EUR
500 million plus royalties. TB-403 is scheduled to enter a Phase Ib
clinical trial in mid-2008 for the treatment of cancer.

ThromboGenics has built strong links with the University of Leuven and
the Flanders Institute for Biotechnology (VIB) and has exclusive rights to
certain therapeutics developed at these institutions. ThromboGenics is
headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland
and New York, U.S. The Company is listed on Eurolist by Euronext Brussels
under the symbol THR. More information is available at
http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on The Nordic Exchange (OMXS:BINV),
is a research-based pharmaceutical company that focuses on developing
antibody drugs. The Company is currently running innovative drug projects
within the areas of thrombosis, cancer, atherosclerosis and ophthalmic
diseases. In January 2007 the Company announced a major strategic alliance
with American-based Genentech, Inc. in the cardiovascular field. These
projects are based on a competitive and in substance patented technology
platform. The scope and strength of this platform is also utilised by
partners, such as ALK-Abelló, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB
and XOMA.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's
leading research-focused healthcare groups in the fields of pharmaceuticals
and diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, and is a
market leader in virology. It is also active in other major therapeutic
areas such as autoimmune diseases, inflammatory and metabolic disorders and
diseases of the central nervous system. In 2007 sales by the
Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the
Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D
agreements and strategic alliances with numerous partners, including
majority ownership interests in Genentech and Chugai, and invested over 8
billion Swiss francs in R&D in 2007. Worldwide, the group employs about
79,000 people. Additional information is available on the Internet at
http://www.roche.com.

(Date:12/9/2016)... 2016 The research report by ... in the Global Label-Free Array Systems Market accounted for ... 2015. Players such as Biacore, Agilent Technologies, ForteBio, Molecular ... the global market due to their unmatched product portfolio ... upgrades and timely product launches are expected to be ...

(Date:12/9/2016)... China Cord Blood Corporation (NYSE: CO ... leading provider of cord blood collection, laboratory testing, hematopoietic stem ... results of its 2016 Annual General Meeting, which was held ... China . At the Annual General ... KPMG Huazhen LLP as the independent auditors of the Company ...

(Date:12/9/2016)... , December 9, 2016 According to a ... (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, ... 2021" published by MarketsandMarkets, the global market is expected to reach ... at a CAGR of 10.6% during the forecast period. ... ...

(Date:11/21/2016)... Nov. 21, 2016 Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...

(Date:11/15/2016)... Md. , Nov. 15, 2016 Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...

(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...